193739-32-1

Basic information

• Product Name: (±)-trans-2-[2-(4-Chlorophenylsulfanyl)ethoxy]-3-methoxy-5-[5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl]benzonitrile
• CAS NO: 193739-32-1
• Molecular Formula: C₂₉H₃₀ClNO₆S
• Molecular Weight: 556.08255
• Mol File: 193739-32-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (±)-trans-2-[2-(4-Chlorophenylsulfanyl)ethoxy]-3-methoxy-5-[5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl]benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: (±)-trans-2-[2-(4-Chlorophenylsulfanyl)ethoxy]-3-methoxy-5-[5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl]benzonitrile(193739-32-1)
• EPA Substance Registry System: (±)-trans-2-[2-(4-Chlorophenylsulfanyl)ethoxy]-3-methoxy-5-[5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl]benzonitrile(193739-32-1)

Safety Data

• Hazardous Substances Data: 193739-32-1(Hazardous Substances Data)

Usage

General Description

The chemical compound "(±)-trans-2-[2-(4-Chlorophenylsulfanyl)ethoxy]-3-methoxy-5-[5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl]benzonitrile" is a complex molecule with several functional groups. It contains a benzonitrile group, a methoxy group, a tetrahydrofuran ring, and a chlorophenylsulfanyl group. (±)-trans-2-[2-(4-Chlorophenylsulfanyl)ethoxy]-3-methoxy-5-[5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl]benzonitrile has potential applications as a pharmaceutical agent or as a chemical intermediate in organic synthesis. Its unique structure and combination of functional groups make it an interesting target for further study in medicinal and synthetic chemistry.

Upstream product

• 205654-33-7 Trans-2-(3-Methoxy-4-p-chlorophenylthioethoxy-5-iodophenyl)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran 
• 245469-66-3 1-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl]-4-(3,4,5-trimethoxyphenyl)butane-1,4-dione 
• 245469-67-4 1-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl]-4-(3,4,5-trimethoxyphenyl)-1,4-butanediol 
• 245469-62-9 3-(N,N-dimethylamino)-1-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl]propan-1-one 
• 245469-65-2 1-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl]prop-2-en-1-one 
• 245469-59-4 ethanone-1-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl] 
• 245469-58-3 ethanone-1-[3-methoxy-4-(2-bromoethoxy)-5-iodophenyl] 
• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 
• 103440-59-1 1-(4-hydroxy-3-iodo-5-methoxy-phenyl)ethan-1-one 
• 544-92-3 copper(I) cyanide 
• 245469-68-5 2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-iodophenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran 
• 154544-30-6 1-(3-methoxy-4-hydroxyethoxy-5-iodophenyl)-4-(3,4,5-trimethoxyphenyl)-1,4-butanedione 
• 5438-36-8 5-iodovaniline 
• 106-54-7 p-Chlorothiophenol 

Relevant articles and documents

PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS

A pharmaceutical formulation is provided for the treatment of inflammatory and/or immune disorders, particularly those mediated by platelet activating factor (“PAF”) or a product of 5-lipoxygenase. The formulation, in one embodiment, is an essentially anhydrous ointment containing an active agent selected from the group consisting of 2,5-diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 2,4-diaryl tetrahydrofurans, 2,4-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes, 2,4-diaryl pyrrolidines, and 2,5-diaryl pyrrolidines, and an enhancer composition containing one or more C3-18 esters such as diethyl succinate, propylene carbonate, diisopropyl adipate and glyceryl triacetate. In another embodiment, the formulation is a cream, gel, lotion, oil, or the like, containing the: active agent in crystalline form. The invention also encompasses the novel crystalline form of the active agent, and methods for using the formulations to treat individuals with inflammatory and/or immune disorders. Also encompassed is use of isopropyl alcohol (IPA) to enhance stability of the active agent and pharmaceutical formulations.

(±)-Trans-2-[3-methoxy-4-(4-chlorophenyl thioethoxy)-5-cyanophenyl]-5- (3,4,5-trimethoxyphenyl)tetrahydrofuran, a potent PAF-receptor antagonist

The synthesis of (±)-trans-2-[3-methoxy-4- (chlorophenylthioethoxyphenyl)-5-cyanophenyl]-5-(3,4,5- trimethoxyphenyl)tetrahydrofuran from commercially available acetovanillone and 3,4,5-trimethoxybenzaldehyde is described.